Bruker launches MOVE-T for dairy quality control

Published 28/05/2025, 12:14
Bruker launches MOVE-T for dairy quality control

ETTLINGEN, Germany - Bruker Corporation (NASDAQ:BRKR), a scientific instruments manufacturer with a market capitalization of $5.6 billion, has introduced the MOVE-T, an innovative liquid dairy analyzer employing Fourier Transform Near-Infrared (FT-NIR) technology for enhanced quality control in the dairy industry. The MOVE-T aims to set a new standard in the precision analysis of raw milk and other liquid dairy products, promoting superior product quality and consistency.

The MOVE-T, a compact and integrated device, is tailored for sectors processing liquid dairy products or plant-based drinks. Its advanced FT-NIR technology combined with a wear-free quartz cell offers high sensitivity and specificity. This technology ensures precise and reliable results, in line with ISO 21543 (IDF 201), and is anticipated to become an essential tool for modern dairy quality control.

Katharina Baumgartner, Dairy Laboratory Specialist at GOLDSTEIG Cheese Factories Bayerwald GmbH, expressed satisfaction with the MOVE-T, highlighting its seamless integration into existing workflows and the exceptional transferability of methods and results for key products in quality control. According to InvestingPro data, Bruker’s commitment to innovation is reflected in its strong revenue growth of 14.8% and impressive gross profit margin of 49.9%.

Dr. Jörg-Peter Conzen, Vice-President of Bruker Optics, emphasized the company’s commitment to innovation and analytical excellence. He noted that the MOVE-T completes Bruker’s portfolio of dairy FT-NIR analyzers and is expected to help customers achieve greater efficiency and product consistency.

Bruker Corporation, known for its high-performance scientific instruments and analytical and diagnostic solutions, continues to support scientific and industrial communities in their quest for precision and efficiency. The MOVE-T is a reflection of Bruker’s dedication to advancing technology in the post-genomic era, focusing on applications that improve human life quality.

This announcement is based on a press release statement from Bruker Corporation.

In other recent news, Bruker Corporation has reported its first-quarter 2025 earnings, surpassing analyst expectations with an earnings per share (EPS) of $0.47 compared to the forecast of $0.42. The company also exceeded revenue projections, reporting $801.4 million against the anticipated $764.72 million. Despite these positive results, the company faces challenges, particularly in the academic government market, which is expected to decline by 20-25% this year. The company maintains its full-year 2025 revenue guidance between $3.48 billion and $3.55 billion.

In terms of analyst perspectives, Citi downgraded Bruker from Buy to Neutral, citing concerns over exposure to the U.S. Academic and Government market and potential tariff impacts. Citi also lowered its price target for Bruker to $40 from $50. Similarly, Stifel adjusted its price target from $57 to $48 while maintaining a Hold rating. Stifel’s analysis points to more conservative growth expectations due to deteriorating academic trends and tariff effects.

Despite these challenges, Bruker continues to focus on mitigating tariff impacts and anticipates potential earnings growth in the latter half of 2025. The company’s management remains optimistic about strategic direction and ongoing investments in high-growth areas.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.